Consistent with a positive role of TNF-α on NF-κB activity [49] and a potential mediation of HAS3 expression by TNF-α, we detected a dose-dependent increase of HAS3 mRNA expression and canonical NF-κB activation in TNF-α-treated oral cancer cells. The gene discussed is HAS3; the disease is lip and oral cavity carcinoma.